This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pepperl, S.
Right arrow Articles by Plachter, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pepperl, S.
Right arrow Articles by Plachter, B.

 Previous Article  |  Next Article 

Journal of Virology, July 2000, p. 6132-6146, Vol. 74, No. 13
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Dense Bodies of Human Cytomegalovirus Induce both Humoral and Cellular Immune Responses in the Absence of Viral Gene Expression

Sandra Pepperl,1 Jürgen Münster,1 Michael Mach,2 J. Robin Harris,3 and Bodo Plachter1,*

Institute for Virology1 and Institute for Zoology,3 University of Mainz, Mainz, and Institute for Clinical and Molecular Virology, University of Erlangen-Nürnberg, Erlangen,2 Germany

Received 14 March 2000/Accepted 10 April 2000

Infection of fibroblast cell cultures with human cytomegalovirus (HCMV) leads to the production of significant amounts of defective enveloped particles, termed dense bodies (DB). These noninfectious structures contain major antigenic determinants which are responsible for induction of both the humoral and the cellular immune response against HCMV. We tested the hypothesis that, by virtue of their unique antigenic and structural properties, DB could induce a significant immune response in the absence of infectious virus. Mice were immunized with gradient-purified DB, which were either left untreated or subjected to sequential rounds of sonication and freeze-thawing to prevent cellular entry. Titers of neutralizing antibodies induced by DB were in a range comparable to levels present in convalescent human sera. The virus-neutralizing antibody response was surprisingly durable, with neutralizing antibodies detected 12 months following primary immunization. The HCMV-specific major histocompatibility complex class I-restricted cytolytic T-cell (CTL) response was assayed using mice transgenic for the human HLA-A2 molecule. Immunization with DB led to high levels of HCMV-specific CTL in the absence of de novo viral protein synthesis. Maximal total cytolytic activity in mice immunized with DB was nearly as efficient as the cytolytic activity induced by a standard immunization with murine cytomegalovirus. Furthermore, DB induced a typical T-helper 1 (Th1)-dominated immune response in mice, as determined by cytokine and immunoglobulin G isotype analysis. Induction of humoral and cellular immune responses was achieved without the concomitant use of adjuvant. We thus propose that DB can serve as a basis for the future development of a recombinant nonreplicating vaccine against HCMV. Finally, such particles could be engineered for efficient delivery of antigens from other pathogens to the immune system.

* Corresponding author. Mailing address: Institut für Virologie, Johannes Gutenberg-Universität Mainz, Obere Zahlbacher Str. 67, 55101 Mainz, Germany. Phone: (49)-6131-3933652. Fax: (49)-6131-3935604. E-mail: plachter{at}mail.uni-mainz.de.

Journal of Virology, July 2000, p. 6132-6146, Vol. 74, No. 13
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Mersseman, V., Besold, K., Reddehase, M. J., Wolfrum, U., Strand, D., Plachter, B., Reyda, S. (2008). Exogenous introduction of an immunodominant peptide from the non-structural IE1 protein of human cytomegalovirus into the MHC class I presentation pathway by recombinant dense bodies. J. Gen. Virol. 89: 369-379 [Abstract] [Full Text]  
  • Besold, K., Frankenberg, N., Pepperl-Klindworth, S., Kuball, J., Theobald, M., Hahn, G., Plachter, B. (2007). Processing and MHC class I presentation of human cytomegalovirus pp65-derived peptides persist despite gpUS2-11-mediated immune evasion. J. Gen. Virol. 88: 1429-1439 [Abstract] [Full Text]  
  • Delmas, S., Martin, L., Baron, M., Nelson, J. A., Streblow, D. N., Davignon, J.-L. (2005). Optimization of CD4+ T Lymphocyte Response to Human Cytomegalovirus Nuclear IE1 Protein through Modifications of Both Size and Cellular Localization. J. Immunol. 175: 6812-6819 [Abstract] [Full Text]  
  • Morello, C. S., Ye, M., Hung, S., Kelley, L. A., Spector, D. H. (2005). Systemic Priming-Boosting Immunization with a Trivalent Plasmid DNA and Inactivated Murine Cytomegalovirus (MCMV) Vaccine Provides Long-Term Protection against Viral Replication following Systemic or Mucosal MCMV Challenge. J. Virol. 79: 159-175 [Abstract] [Full Text]  
  • McGregor, A., Liu, F., Schleiss, M. R. (2004). Molecular, Biological, and In Vivo Characterization of the Guinea Pig Cytomegalovirus (CMV) Homologs of the Human CMV Matrix Proteins pp71 (UL82) and pp65 (UL83). J. Virol. 78: 9872-9889 [Abstract] [Full Text]  
  • Hebeis, B. J., Klenovsek, K., Rohwer, P., Ritter, U., Schneider, A., Mach, M., Winkler, T. H. (2004). Activation of Virus-specific Memory B Cells in the Absence of T Cell Help. JEM 199: 593-602 [Abstract] [Full Text]  
  • Odeberg, J., Plachter, B., Branden, L., Soderberg-Naucler, C. (2003). Human cytomegalovirus protein pp65 mediates accumulation of HLA-DR in lysosomes and destruction of the HLA-DR {alpha}-chain. Blood 101: 4870-4877 [Abstract] [Full Text]  
  • Gerna, G., Lilleri, D., Baldanti, F., Torsellini, M., Giorgiani, G., Zecca, M., De Stefano, P., Middeldorp, J., Locatelli, F., Revello, M. G. (2003). Human cytomegalovirus immediate-early mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoietic stem cell transplantation: a prospective, randomized, open-label trial. Blood 101: 5053-5060 [Abstract] [Full Text]  
  • Gallez-Hawkins, G., Villacres, M. C., Li, X., Sanborn, M. C., Lomeli, N. A., Zaia, J. A. (2003). Use of Transgenic HLA A*0201/Kb and HHD II Mice To Evaluate Frequency of Cytomegalovirus IE1-Derived Peptide Usage in Eliciting Human CD8 Cytokine Response. J. Virol. 77: 4457-4462 [Abstract] [Full Text]  
  • La Rosa, C., Wang, Z., Brewer, J. C., Lacey, S. F., Villacres, M. C., Sharan, R., Krishnan, R., Crooks, M., Markel, S., Maas, R., Diamond, D. J. (2002). Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice. Blood 100: 3681-3689 [Abstract] [Full Text]  
  • Revello, M. G., Gerna, G. (2002). Diagnosis and Management of Human Cytomegalovirus Infection in the Mother, Fetus, and Newborn Infant. Clin. Microbiol. Rev. 15: 680-715 [Abstract] [Full Text]  
  • Wills, M R, Carmichael, A J, Sissons, J G P (2002). Vaccines against persistent DNA virus infections. Br Med Bull 62: 125-138 [Abstract] [Full Text]  
  • Song, B. H., Lee, G. C., Moon, M. S., Cho, Y. H., Lee, C. H. (2001). Human cytomegalovirus binding to heparan sulfate proteoglycans on the cell surface and/or entry stimulates the expression of human leukocyte antigen class I. J. Gen. Virol. 82: 2405-2413 [Abstract] [Full Text]  
  • Holtappels, R., Podlech, J., Grzimek, N. K. A., Thomas, D., Pahl-Seibert, M.-F., Reddehase, M. J. (2001). Experimental Preemptive Immunotherapy of Murine Cytomegalovirus Disease with CD8 T-Cell Lines Specific for ppM83 and pM84, the Two Homologs of Human Cytomegalovirus Tegument Protein ppUL83 (pp65). J. Virol. 75: 6584-6600 [Abstract] [Full Text]  
  • Koelle, D. M., Chen, H. B., Gavin, M. A., Wald, A., Kwok, W. W., Corey, L. (2001). CD8 CTL from Genital Herpes Simplex Lesions: Recognition of Viral Tegument and Immediate Early Proteins and Lysis of Infected Cutaneous Cells. J. Immunol. 166: 4049-4058 [Abstract] [Full Text]  
  • Zaia, J. A., Sissons, J.G. P., Riddell, S., Diamond, D. J., Wills, M.R., Carmichael, A.J., Weekes, M.P., Gandhi, M., La Rosa, C., Villacres, M., Lacey, S., Markel, S., Sun, J. (2000). Status of Cytomegalovirus Prevention and Treatment in 2000. ASH Education Book 2000: 339-355 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»